For the Inventor, By the Inventor

Enter assignee name

Brisbane, CA, United States of America

Sangamo Therapeutics, Inc.

USPTO Granted Patents = 145

CIPO Patents = 20

EPO Patents = 71

Forward Citations = 543

Loading Chart...

Loading Chart...

113 inventors (with patents filed for the assignee):

Jeffrey C Miller (49 out of 86 patents)

Edward J Rebar (44 out of 88 patents)

Fyodor Urnov (33 out of 80 patents)

4. David Paschon (30 out of 49 patents)

5. Michael C Holmes (30 out of 64 patents)

6. Philip D Gregory (24 out of 62 patents)

7. Lei Zhang (23 out of 43 patents)

8. H Steve Zhang (16 out of 26 patents)

9. Andreas Reik (16 out of 22 patents)

10. Dmitry Y Guschin (15 out of 21 patents)

11. Gregory J Cost (15 out of 25 patents)

12. Anthony Conway (13 out of 14 patents)

13. Jianbin Wang (12 out of 18 patents)

14. Gary K Lee (10 out of 15 patents)

15. Steven Robert Webb (10 out of 41 patents)

Core Competencies:

Gene Editing

AAV Engineering

Nuclease Technology

Transgene Regulation

Tau Protein Modulation

Huntington's Disease Treatment

Cystic Fibrosis Gene Modification

Lysosomal Storage Diseases

T Cell Receptor Disruption

Base Editing

Gene Inactivation

Cytokine Modulation

145 patents: Sort by Forward Citations

1. 12318427 - Methods and compositions for modulation of tau proteins (2025-06-03),

2. 12139517 - Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof (2024-11-12),

3. 12043650 - Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene (2024-07-23),

4. 11981967 - Engineering AAV (2024-05-14),

5. 11920169 - Compositions for linking DNA-binding domains and cleavage domains (2024-03-05),

6. 11898158 - Methods and compositions for the treatment of lysosomal storage diseases (2024-02-13),

7. 11859190 - Methods and compositions for regulation of transgene expression (2024-01-02),

8. 11857641 - Method for the treatment of mucopolysaccharidosis type I (2024-01-02),

9. 11845965 - Regulation of gene expression using engineered nucleases (2023-12-19),

10. 11834686 - Engineered target specific base editors (2023-12-05),

11. 11827900 - Engineered target specific nucleases (2023-11-28),

12. 11793888 - Methods and compositions for engineering immunity (2023-10-24),

13. 11725218 - Artificial nucleases comprising engineered cleavage half-domains (2023-08-15),

14. 11725192 - Separation and quantification of empty and full viral capsid particles (2023-08-15),

15. 11723952 - Methods and compositions for treating Huntington's Disease (2023-08-15),

Sangamo Therapeutics, Inc. is a biotechnology company focused on translating groundbreaking genome editing technology into novel therapeutics for genetic diseases. The company aims to create transformative genomic medicines using their proprietary zinc finger nuclease (ZFN) and CRISPR/Cas9 platforms. Sangamo's goal is to develop innovative treatments for a wide range of diseases, including genetic disorders, neurodegenerative diseases, and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

145 Patents

#2 in Brisbane, CA

#602 in California

#2,608 in US

#5,474 in the World

Brisbane, CA, United States of America

Sangamo Therapeutics, Inc.

Forward Citations = 543

113 inventors:

Jeffrey C Miller (49 out of 86 patents)

Edward J Rebar (44 out of 88 patents)

Fyodor Urnov (33 out of 80 patents)

4. David Paschon (30 out of 49 patents)

5. Michael C Holmes (30 out of 64 patents)

Please report any incorrect information to support@idiyas.com

Loading…